The global diabetes management market size was valued at USD 41.71 billion in 2025 and is projected to grow from USD 49.91 billion in 2026 to USD 209.63 billion by 2034, registering a CAGR of 19.65% during the forecast period from 2026 to 2034. North America dominated the diabetes management market with a market share of 39.4% in 2025.
Diabetes Management encompasses products, technologies, and services used to monitor blood glucose levels, administer insulin, and support the long-term management of diabetes. It includes glucose monitoring devices, insulin delivery systems, digital health platforms, and therapeutic solutions. The rising prevalence of diabetes, increasing adoption of continuous glucose monitoring (CGM), technological advancements, and growing awareness of preventive healthcare are driving innovation and improving patient outcomes globally.
Download a Free Sample To learn more about this report,
Increasing Adoption of Integrated Diabetes Technology
Diabetes management is increasingly shifting toward connected systems that combine glucose monitoring, insulin delivery, and digital data management. Automated insulin delivery systems can use continuous glucose monitoring data to adjust insulin administration, reducing the need for patients to make every dosing decision manually. This integration is moving diabetes management from individual devices toward coordinated technology ecosystems.
In January 2026, the American Diabetes Association's updated Standards of Care recommended automated insulin delivery systems as the preferred insulin-delivery approach for people with type 1 diabetes who can use the technology safely.
Growing Use of Continuous Glucose Monitoring Beyond Insulin Users
Continuous glucose monitoring is expanding beyond its traditional concentration among people using intensive insulin therapy. Healthcare providers are increasingly considering CGM for people with type 2 diabetes who use non-insulin glucose-lowering medications, while over-the-counter systems are also broadening access to glucose information. This is expanding the role of continuous monitoring across a wider range of diabetes-management pathways.
In January 2025, the American Diabetes Association added a recommendation to consider real-time or intermittently scanned CGM for adults with type 2 diabetes using glucose-lowering medications other than insulin.
Rising Global Diabetes Prevalence Expands the Treatment Population
The increasing number of people living with diabetes is creating sustained demand for glucose-lowering medicines, monitoring technologies, insulin-delivery systems, education, and disease-management services. Diabetes requires continuing management to control blood glucose and reduce the risk of complications, making the expanding patient population a fundamental source of demand across the diabetes-management ecosystem.
In November 2024, the World Health Organization reported that the number of people living with diabetes had increased from 200 million in 1990 to 830 million in 2022.
Limited Treatment Access in Lower-Resource Settings
Diabetes management depends on consistent access to medicines, monitoring supplies, healthcare professionals, and follow-up care. In lower-resource settings, limited availability and affordability of these services can prevent patients from maintaining recommended treatment plans. Unequal healthcare access therefore restricts the adoption of advanced management solutions and reduces treatment continuity.
In November 2024, the World Health Organization reported that more than half of people living with diabetes did not take diabetes medication in 2022, with treatment coverage lowest in low- and middle-income countries.
Expansion of Digital and Virtual Diabetes Management
Digital health platforms, connected devices, mobile applications, and virtual coaching can extend diabetes-management support beyond conventional clinical visits. These tools can help patients interpret glucose information, track treatment behavior, receive education, and communicate with healthcare professionals remotely. Greater integration of digital services with diabetes-management programs creates opportunities to improve continuity of care and reach underserved patient populations.
In January 2025, the American Diabetes Association recommended considering combinations of CGM, insulin pumps, diabetes applications, and online or virtual coaching to improve glycemic outcomes in people with diabetes or prediabetes.
Complexity of Diabetes Technology Can Hinder Effective Use
Modern diabetes-management systems require patients and healthcare professionals to understand device operation, data interpretation, troubleshooting, and treatment adjustments. Rapid technology development can also make it difficult for clinical teams to remain familiar with newly introduced systems. Without appropriate training and ongoing support, technological complexity can reduce effective utilization even when devices are available.
In January 2026, the American Diabetes Association emphasized that users of automated insulin delivery systems should receive education on device operation and troubleshooting at regular intervals, reflecting the continuing challenge of managing increasingly complex diabetes technologies.
Monitoring Devices Segment Dominated the Market with 38.6% Share in 2025
The monitoring devices segment dominated the global diabetes management market with a 38.6% share in 2025, driven by the growing adoption of continuous glucose monitoring (CGM) systems, blood glucose meters, and real-time diabetes tracking solutions. Rising diabetes prevalence, increasing patient awareness, and continuous technological advancements continue to strengthen the segment's leading market position.
The diagnostic devices segment is expanding steadily due to increasing demand for early diabetes detection, routine screening, and laboratory-based diagnostic solutions. Growing emphasis on preventive healthcare is supporting segment growth.
The insulin delivery devices segment is witnessing steady growth owing to increasing adoption of advanced insulin administration technologies, improved patient convenience, and the growing preference for personalized diabetes care.
Request Customizationto receive a tailored report.
Other Devices Segment is Projected to Register the Fastest Growth at a CAGR of 9.1%
The other devices segment is projected to register the fastest growth at a CAGR of 9.1% during 2026–2034, driven by increasing adoption of smart diabetes monitoring technologies, connected health devices, and digital diabetes management solutions. Continuous innovation in wearable and AI-enabled monitoring systems is expected to further accelerate segment growth.
The continuous glucose monitoring (CGM) segment continues to maintain a significant market presence due to its ability to provide real-time glucose readings, improve glycemic control, and reduce the need for frequent finger-prick testing.
The self-monitoring blood glucose (SMBG) devices segment is witnessing steady growth owing to their affordability, ease of use, and widespread adoption among patients requiring regular blood glucose monitoring.
Hemoglobin A1C Meters Segment is Projected to Register the Fastest Growth at a CAGR of 7.4%
The hemoglobin A1C meters segment is projected to register the fastest growth at a CAGR of 7.4% during 2026–2034, driven by increasing demand for long-term glucose monitoring, early diagnosis of diabetes, and routine disease management. Growing awareness regarding preventive healthcare and regular diabetes screening is supporting segment expansion.
The blood glucose analyzers segment continues to witness strong demand owing to their widespread use in hospitals, diagnostic laboratories, and clinical settings for accurate diabetes diagnosis and monitoring.
The other diagnostic devices segment is expanding steadily due to technological advancements in point-of-care diagnostics and increasing accessibility of rapid testing solutions.
Insulin Pumps Segment is Projected to Register the Fastest Growth at a CAGR of 9.4%
The insulin pumps segment is projected to register the fastest growth at a CAGR of 9.4% during 2026–2034, driven by increasing adoption of automated insulin delivery systems, advancements in wearable technologies, and growing demand for personalized diabetes management. Improved treatment accuracy and enhanced patient convenience are expected to further support segment growth.
The insulin pens segment continues to maintain a significant market presence due to their ease of use, portability, and widespread adoption among patients requiring daily insulin therapy.
The insulin syringes segment is witnessing steady growth owing to their affordability, broad availability, and continued use in healthcare facilities and home-based diabetes management.
Artificial Pancreas Segment is Projected to Register the Fastest Growth at a CAGR of 12.8%
The artificial pancreas segment is projected to register the fastest growth at a CAGR of 12.8% during 2026–2034, driven by rapid advancements in closed-loop insulin delivery systems, integration with continuous glucose monitoring technologies, and increasing demand for automated diabetes care. Continuous innovation and improving clinical outcomes are expected to further accelerate market growth.
The smart diabetes management devices segment is expanding steadily due to increasing integration of mobile applications, cloud-based monitoring platforms, and remote patient management solutions.
The other advanced diabetes devices segment is witnessing steady growth owing to ongoing technological innovations and growing investments in next-generation diabetes care technologies.
Injectables Segment Dominated the Market with 58.3% Share in 2025
The injectables segment dominated the global diabetes management market with a 58.3% share in 2025, owing to the widespread use of insulin and GLP-1 receptor agonists for effective blood glucose control. Increasing prevalence of both type 1 and advanced type 2 diabetes, along with continuous innovation in injectable therapies, continues to reinforce the segment's leading position.
The oral drugs segment is expanding steadily due to the growing use of convenient oral antidiabetic medications, increasing treatment adherence, and continuous development of novel drug classes.
Exenatide Segment is Projected to Register the Fastest Growth at a CAGR of 8.9%
The Exenatide segment is projected to register the fastest growth at a CAGR of 8.9% during 2026–2034, driven by increasing adoption of GLP-1 receptor agonists, growing focus on glycemic control with weight management, and expanding clinical recommendations. Continuous product innovation and rising patient preference for advanced injectable therapies are expected to support segment growth.
The insulin segment continues to dominate injectable diabetes treatment due to its essential role in managing type 1 diabetes and advanced type 2 diabetes. Increasing availability of long-acting and rapid-acting insulin formulations continues to drive demand.
The other injectable therapies segment is witnessing steady growth owing to ongoing research, combination therapies, and the introduction of innovative biologic treatments for diabetes management.
Dipeptidyl Inhibitors Segment is Projected to Register the Fastest Growth at a CAGR of 7.6%
The dipeptidyl inhibitors segment is projected to register the fastest growth at a CAGR of 7.6% during 2026–2034, driven by their favorable safety profile, low risk of hypoglycemia, and increasing use in combination therapy for type 2 diabetes. Rising demand for effective oral medications with improved patient compliance is expected to further support market growth.
The biguanides segment continues to maintain a strong market presence due to their established role as first-line therapy for type 2 diabetes and widespread clinical acceptance.
The other oral antidiabetic drugs segment is witnessing steady growth owing to continuous innovation in oral diabetes therapeutics, expanding treatment options, and increasing focus on personalized diabetes care.
Speak to an Analystto discuss market opportunities.
North America diabetes management market accounted for 39.4% of the global market, reaching USD 16.43 billion in 2025, and is projected to grow at a CAGR of 7.2% during the forecast period. The region continues to lead due to the high prevalence of diabetes, widespread adoption of continuous glucose monitoring (CGM) systems, insulin delivery devices, and strong healthcare spending. Ongoing technological advancements and supportive reimbursement policies are further accelerating market growth.
The U.S. market was valued at USD 13.64 billion in 2025, making it the largest contributor in North America. Rising adoption of smart insulin pens, insulin pumps, CGM devices, digital diabetes management platforms, and increasing awareness of preventive care continue to strengthen market growth.
Canada's market reached USD 2.79 billion in 2025. Growing prevalence of diabetes, expanding access to advanced glucose monitoring technologies, and increasing government initiatives for chronic disease management continue to support steady market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe diabetes management market accounted for 27.1% of the global market, reaching USD 11.30 billion in 2025, and is expected to register a CAGR of 6.9% during the forecast period. Increasing healthcare investments, rising adoption of digital health technologies, growing elderly population, and continuous innovation in diabetes care devices are driving regional market growth.
The UK market was valued at USD 2.49 billion in 2025. Expanding use of continuous glucose monitoring systems, increasing awareness of diabetes prevention, and strong support from the public healthcare system continue to boost market demand.
Germany's market accounted for USD 3.39 billion in 2025. Advanced healthcare infrastructure, widespread adoption of insulin delivery technologies, and increasing demand for connected diabetes care solutions continue to support market expansion.
Asia Pacific diabetes management market accounted for 22.8% of the global market, valued at USD 9.51 billion in 2025, and is projected to register a CAGR of 9.6% during the forecast period. Rapid urbanization, rising diabetes prevalence, improving healthcare access, and increasing adoption of digital health and wearable monitoring devices are accelerating regional market growth.
Japan's market generated USD 1.90 billion in 2025. Growing elderly population, increasing demand for advanced diabetes monitoring devices, and strong adoption of innovative healthcare technologies continue to support market growth.
China's market accounted for USD 5.23 billion in 2025, representing the largest share within Asia Pacific. Rising diabetic population, expanding healthcare infrastructure, increasing use of CGM devices, and growing government initiatives for chronic disease management continue to drive market expansion.
Latin America diabetes management market accounted for 6.2% of the global market, totaling USD 2.59 billion in 2025, and is anticipated to grow at a CAGR of 7.7% during the forecast period. Increasing awareness of diabetes care, improving healthcare infrastructure, and expanding access to glucose monitoring and insulin delivery devices are supporting regional market growth.
Brazil's market was valued at USD 1.58 billion in 2025. Rising diabetes prevalence, increasing healthcare investments, growing adoption of advanced monitoring technologies, and expanding access to specialty diabetes care continue to support market demand.
Middle East & Africa diabetes management market accounted for 4.5% of the global market, totaling USD 1.88 billion in 2025, and is anticipated to grow at a CAGR of 8.1% during the forecast period. Increasing incidence of diabetes, rising healthcare expenditure, expanding access to modern diabetes care technologies, and growing awareness of disease management are contributing to regional market expansion.
The UAE market was valued at USD 0.53 billion in 2025. High diabetes prevalence, increasing investments in digital healthcare, growing adoption of advanced glucose monitoring systems, and strong government initiatives to improve chronic disease management continue to drive market growth.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Diabetic Retinopathy Market Size, Share, Growth, Analysis, 2034
Acne Treatment Market Size, Share & Growth Graph by 2034
Anti-HIV Drugs Market Size, Share, Growth, Analysis, Report, 2034
Contrast Agents in MRI Market Size, Share, Growth, Analysis, 2034
Bone Metastasis Market Size, Share, Growth, Analysis, Report, 2034
Concussion Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com